

This form outlines the information required to submit a treatment plan request through the [Eviti Connect Oncology application](#).

A clinical team member from your practice can assist in completing this checklist to ensure all necessary details are available when entering the treatment plan request.

All documentation should be uploaded during submission or emailed (mr@eviti.com) or faxed (888-468-1423) to the Eviti Medical Office.

For questions, please contact the Eviti Support Team: clientsupport@nanthealth.com

Patient Information

Patient Name			
Patient Date of Birth		Male	Female
Patient Zip Code		Date of Diagnosis	
Insurance Plan			
Insurance ID			

Provider Information

Physician Name			
Practice TIN		Physician NPI	
Submitter Name			
Submitter Phone		Submitter Fax	
Submitter Email			

Patient Treatment Details

Patient Detail →	Height	in	cm	Weight	lb	kg
Cancer Type (<i>site</i>)						
ICD-10 Code:						
Pathology						
Current stage of disease (<i>e.g. Stage IIa, Recurrent</i>)						
Metastasis (<i>If applicable</i>) →	Metastasis site(s)		Diagnosis date			
Line of Therapy (<i>choose one</i>)	Adjuvant	Neoadjuvant	1st line	2nd line	3rd line	3rd line +
Goal of Therapy / Intent of Therapy (<i>choose one</i>)	Curative			Non-curative		
Total number of cycles planned		Cycle length (<i>days</i>)				
Is this a clinical trial?	Yes	No	Clinical trial ID or name			
Treatment Start Date (<i>C1D1</i>)		Give until progression	Yes	No		
Regimen Name (<i>e.g. R-CHOP, TAC</i>)						

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Include all IV and oral medications in the regimen (chemotherapy, targeted therapy, pre-meds, antiemetics, growth factor injections and or other supportive meds) in one preauthorization.

Refer to the chemotherapy orders. Attach a document with additional drugs, if necessary.

Drug Name <i>Indicate if IV or oral</i>	Dose and Units <i>(e.g. 60 mg/m2)</i>	Delivered Dose <i>(e.g. 120 mg)</i>	Schedule <i>(e.g. D1, D1-3)</i>	J-code

Site of Service

Patient Type <i>(Select One)</i>	Inpatient		Outpatient	
Site Name				
Site City or Zip Code				
Site TIN		Site NPI		

Medication Source

Select one medication source	Pharmacy	Buy and Bill
-------------------------------------	----------	--------------

If you do not receive an automated Eviti code, the request goes to Eviti for review. Please attach the following documents to the online treatment plan:

- Progress note(s) with plan of care
- Pathology
- Recent lab reports (e.g. CBC, ANC)
- Scans if relative to this treatment plan
- Chemotherapy checklist
- Genomic test report, if applicable
- Any information that addresses the issues noted on the Deviation Report

Due to short state-mandated turnaround times, all medical records must be submitted to Eviti at the time of treatment plan submission to facilitate prompt processing and avoid case closure.

If you don't upload the documents online, you can:

- email them to mr@eviti.com
- fax them to **888-468-1423**

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

If molecular marker testing was done, please select the results. Ask a clinical person to help complete this section, if necessary.

Cancer Type	Molecular Marker	Select or Provide Result			
Adrenal	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	
Anal	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
	k-ras Genotype	Wild Type	Mutated	Unknown	
	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	n-ras Genotype	Wild Type	Mutated	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	
Biliary Tract (intrahepatic)	Margin Status	Positive	Negative	Unknown	
	Nodal Status	Positive	Negative	Unknown	
	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	
Bladder	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	Platinum Resistant / Refractory	Yes	No	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	
Bone & Soft Tissue Cancers (Incl. Sarcoma)	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	
Brain	19q Status	Deleted	No Deletion	Unknown	
	1p Status	Deleted	No Deletion	Unknown	
	CD20 Status	Positive	Negative	Unknown	
	MGMT Promoter Status	Methylated	Unmethylated	Negative	Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Breast	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	BRCA 1 Status	Germline Mutation Present	Somatic Mutation Present	Wild Type / No Mutation	Unknown
	BRCA 2 Status	Germline Mutation Present	Somatic Mutation Present	Wild Type / No Mutation	Unknown
	Menopausal Status	Premenopausal Unknown	Perimenopausal N/A Patient is Male	Postmenopausal	
	OncotypeDx® Status	Low	Intermediate or High		Positive
	Estrogen Receptor	Positive	Negative		Unknown
	HER2 / NEU	Equivocal	FISH or CISH Equivocal	FISH or CISH Negative	FISH or CISH Positive
		IHC 1+	IHC 2+	IHC 3+	IHC Negative
		IHC Equivocal	Negative	Unknown	
	NTRK Fusion	Positive	Negative		Unknown
Cervical	PD-L1 Expression (TPS)	1% - 49.9% Negative	50% or greater Unknown		Less than 1%
	Progesterone Receptor	Positive	Negative		Unknown
Cervical	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	PD-L1 Expression (CPS)	1% - 19.9%	20% or greater	Less than 1%	Unknown
Colon	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	k-ras Genotype	Wild Type	Mutated		Unknown
	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
	n-ras Genotype	Wild Type	Mutated		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Esophageal	HER2 / NEU	Equivocal	FISH or CISH Equivocal	FISH or CISH Negative	FISH or CISH Positive
		IHC 1+	IHC 2+	IHC 3+	IHC Negative
		IHC Equivocal	Negative	Unknown	
	PD-L1 Expression (CPS)	1% - 19.9%	20% or greater	Less than 1%	Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Eye	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Gall Bladder	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Gastric (Stomach)	HER2 / NEU	Equivocal	FISH or CISH Equivocal	FISH or CISH Negative	FISH or CISH Positive
		IHC 1+	ICH 2+	IHC 3+	IHC Negative
		IHC Equivocal	Negative	Unknown	
	PD-L1 Expression (CPS)	1% - 19.9%	20% or greater	Less than 1%	Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Gastrointestinal Stromal Tumor (GST)	GIST Risk	High Intermediate	Low		Unknown
	c-kit Status	Exon 11 mutation present	Exon 9 mutation present	No mutation	Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	Imatinib resistant or intolerant	Yes	No		Unknown
	Sunitinib resistant	Yes	No		Unknown
Head and Neck	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	PD-L1 Expression (CPS)	1% - 19.9%	20% or greater	Less than 1%	Unknown
Kidney	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	Prior Therapy	Axitinib	Bevacizumab	Everolimus	Interferon alfa
		Interleukin-2	Pazopanib	Temsirolimus	Sorafenib
		Sunitinib	No Prior Therapy	Unknown	
	Renal Cancer Risk	Good Risk	Intermediate Risk	Poor Risk	Unknown
	Wilms Risk	Favorable	Non-favorable		Unknown

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Leukemia	CD20 Status	Positive	Negative	Unknown	
	Imatinib Resistant or Intolerant	Yes	No	Unknown	
	Philadelphia Chromosome	Positive	Negative	Unknown	
	T315I	Positive	Negative	Unknown	
	CD19 Status	Positive	Negative	Unknown	
	CD22 Status	Positive	Negative	Unknown	
	HIV-Associated Lymphoma	Positive	Negative	Unknown	
	Nodal Size	Total size $\geq$ 10 cm	Total size $\leq$ 10 cm	Unknown	
	Serum LDH Level	High, above normal limits	Within normal limits	Unknown	
	CD33 Status	Positive	Negative	Unknown	
	FLT3 Mutation	Positive	Negative	Unknown	
	IDH1 Mutation	Positive	Negative	Unknown	
	IDH2 Mutation	Positive	Negative	Unknown	
	APL Risk	High Risk	Intermediate Risk	Low Risk	Unknown
	White Blood Cell Count	$\leq$ 10,000 cells / mcl	$>$ 10,000 cells / mcl	Unknown	
	CD30 Status	Positive	Negative	Unknown	
	11q Deletion	Absent	Present	Unknown	
	17p Deletion	Absent	Present	Unknown	
	TP53 Status	Mutation Absent	Mutation Present	Unknown	
	CML Phase	Accelerated Phase Myeloid Blast Phase	Chronic Phase Unknown	Lymphoid Blast Phase	
	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
Liver	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Lung	ALK Status	Positive	Negative	Unknown	
	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
	EGFR	Wild Type	Mutated	Unknown	
	EGFR T790M Mutation	Positive	Negative	Unknown	
	MET Amplification	Positive	Negative	Unknown	
	PD-L1 Expression (CPS)	1% - 19.9%	20% or greater	Less than 1%	Unknown
	RET Gene Rearrangement	Absent	Present	Unknown	
	ROS1 Rearrangement	Positive	Negative	Unknown	
	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	
Lymphoma / Lymphoproliferative Diseases	ALK Status	Positive	Negative	Unknown	
	Nodal Size	Total size ≥ 10 cm	Total Size < 10 cm	Unknown	
	Serum LDH Level	High, above normal limits	Within normal limits	Unknown	
	HIV-Associated Lymphoma	Yes	No	Unknown	
	11q Deletion	Absent	Present	Unknown	
	17p Deletion	Absent	Present	Unknown	
	TP53 Status	Mutation Absent	Mutation Present	Unknown	
	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
	Transplant Candidate	Yes	No	Unknown	
	CD20 Status	Positive	Negative	Unknown	
	CD30 Status	Positive	Negative	Unknown	
	CD52 Status	Positive	Negative	Unknown	
Melanoma	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
	c-kit Status	Exon 11 mutation present	Exon 9 mutation present	Unknown	
	Microsatellite Instability	MSI-L	dMMR/MSI-H	Unknown	
	NTRK Fusion	Positive	Negative	Unknown	

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Mesothelioma	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Myelodysplastic Syndrome (MDS)	PDGFR Mutations	Absent	Present		Unknown
	Risk	V600E Mutation	V600K Mutation	Wild Type	Unknown
	Transplant Candidate	Yes	No		Unknown
	Cytogenetic Abnormalities	Absent	Present		Unknown
	5q Deletion (5q-)	Absent	Present		Unknown
Myeloma	Transplant Candidate	Yes	No		Unknown
Myeloproliferative Disorders	PDGFR Mutations	Absent	Present		Unknown
Ovarian	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	BRCA 1 Status	Germline Mutation Present	Somatic Mutation Present	Wild Type / No Mutation	Unknown
	BRCA 2 Status	Germline Mutation Present	Somatic Mutation Present	Wild Type / No Mutation	Unknown
	Platinum Resistant / Refractory	Yes	No		Unknown
	Paclitaxel-Resistant	Yes	No		Unknown
Pancreatic	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Penile	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Prostate	Castration-Resistant	Yes	No		Unknown
	Prostate Cancer Recurrence Risk	Favorable	Intermediate		High
		Low	Regional		Unfavorable
		Very High	Very Low		Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Rectal	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	n-ras Genotype	Wild Type	Mutated		Unknown
	k-ras Genotype	Wild Type	Mutated		Unknown
	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
Renal Pelvis and Ureter Cancers	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	Platinum Resistant / Refractory	Yes	No		Unknown
Skin (Non-Melanoma)	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Small Intestine	n-ras Genotype	Wild Type	Mutated		Unknown
	k-ras Genotype	Wild Type	Mutated		Unknown
	Obstruction at Resection	Yes	No		Unknown
	Perforation	Yes	No		Unknown
	T4 Lesion	Yes	No		Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Testicular	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	Platinum Resistant / Refractory	Yes	No		Unknown
Thymic	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Thyroid	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	BRAF Status	V600E Mutation	V600K Mutation	Wild Type	Unknown
Unknown Primary	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.

Cancer Type	Molecular Marker	Select or Provide Result			
Urethral	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Uterine	Estrogen Receptor	Positive	Negative		Unknown
	HER2 / NEU	Equivocal	FISH or CISH Equivocal	FISH or CISH Negative	FISH or CISH Positive
		IHC 1+	IHC 2+	IHC 3+	IHC Negative
		IHC Equivocal	Negative	Unknown	
	Progesterone Receptor	Positive	Negative		Unknown
	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Vaginal	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
Vulvar	Microsatellite Instability	MSI-L	dMMR/MSI-H		Unknown
	NTRK Fusion	Positive	Negative		Unknown
	PD-L1 Expression (CPS)	1% - 19.9%	20% or greater	Less than 1%	Unknown
Waldenström's Macroglobulinemia/ Lymphoplasmacytic Lymphoma	Transplant Candidate	Yes	No		Unknown

All documentation should be uploaded during submission or emailed (mr@eviti.com) or faxed (888-468-1423) to the Eviti Medical Office.

For questions please contact the Eviti Support Team: clientsupport@nanthealth.com

Confidentiality Statement: The documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual(s) or entities listed above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you receive this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.